Thursday, 12 November 2026European Markets

Euro Surges 14% Against Dollar, Strongest Performance Since 2022

The Euro has gained 14% against the U.S. dollar in 2025, reaching its highest level since 2022 as broad-based dollar weakness reshapes currency markets. European exporters stand to benefit from improved competitiveness, while carry trade opportunities emerge for European investors amid global monetary policy shifts.

Euro Surges 14% Against Dollar, Strongest Performance Since 2022
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The Euro has climbed 14% against the U.S. dollar in 2025, marking its strongest performance in three years as the greenback falls to levels not seen since 2022.

Major European currencies have posted significant gains, with the British Pound up 7% against the dollar. The Dollar Index tracks a basket of major currencies and reflects broad-based weakness across forex markets.

European exporters gain competitive advantages from the stronger Euro. German manufacturers and French luxury goods producers can now price products more attractively in dollar-denominated markets, particularly in the United States and Asia.

Currency traders face new opportunities and risks. Carry trade strategies—borrowing in low-yield currencies to invest in higher-yielding assets—have attracted investor attention as currency volatility increases.

The Turkish Lira collapsed 17% after carry trade positions unwound, demonstrating the strategy's risks. European investors with exposure to emerging market currencies through carry trades faced substantial losses.

Geopolitical developments contribute to dollar weakness. Progress on Iran-U.S. nuclear deal negotiations has reduced risk premiums that traditionally support dollar demand during international tensions.

The Federal Reserve faces a leadership transition in June 2026, creating uncertainty around U.S. monetary policy direction. Markets anticipate potential policy shifts that could further weaken the dollar.

European institutional investors are repositioning portfolios. Currency hedge costs have dropped for European pension funds and insurers holding U.S. assets, improving returns on dollar-denominated investments.

The Pound trades at €1.13 against the Euro despite its gains versus the dollar, sitting at its lowest level against the Euro since April 2023. UK gilt yields have climbed to 5.21% for 30-year bonds, the highest since 1998.

European currency strength creates challenges for tourism-dependent economies. Spain, Italy, and Greece face headwinds as their destinations become more expensive for American and Asian tourists paying in dollars or dollar-pegged currencies.

Forex analysts monitor the situation closely. Currency markets show 85% confidence in continued dollar weakness based on technical indicators and policy expectations.

European central banks maintain current policy stances. The European Central Bank has not signaled intervention despite the Euro's appreciation, indicating tolerance for current exchange rate levels.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com